Follow The Filings

ARQT Arcutis Biotherapeutics

Arcutis Biotherapeutics earnings company data as of 12:00 PM ET 10/23

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS 0.16 — —
Rev — — —

Insider trades

Open-market buys and sales by ARQT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ARQT insider trades
  • None no insider bought on the open market
  • $3.3M sold by 5 insiders outside a trading plan
  • $9.6M sold by 7 insiders under 10b5-1 plans
  1. Howard G. Welgus Director
    Planned sale
    $127K 4,728 shares at $26.93 12% of stake
    Traded Oct 15 Filed Oct 19
    ↗
  2. Masaru Matsuda See Remarks
    Planned sale
    $92K 3,674 shares at $25.00 3.2% of stake
    Traded Sep 16 Filed Sep 18
    ↗
  3. Howard G. Welgus Director
    Planned sale
    $114K 4,730 shares at $24.18 12% of stake
    Traded Sep 15 Filed Sep 17
    ↗
  4. Masaru Matsuda See Remarks
    Planned sale
    $250K 9,989 shares at $25.03 7.9% of stake
    Traded Sep 8 Filed Sep 10
    ↗
  5. Terrie Curran Director
    Sale
    $956K 38,200 shares at $25.03 62% of stake
    Traded Aug 27 Filed Aug 28
    ↗
  6. Terrie Curran Director
    Sale
    $28K 1,072 shares at $26.04 4.4% of stake
    Traded Aug 20 Filed Aug 24
    ↗
  7. Howard G. Welgus Director
    Planned sale
    $124K 4,730 shares at $26.18 12% of stake
    Traded Aug 17 Filed Aug 19
    ↗
  8. Patrick Burnett See Remarks
    Sale
    $395K 15,000 shares at $26.33 11% of stake
    Traded Aug 11–12 Filed Aug 13
    ↗
  9. Howard G. Welgus Director
    Planned sale
    $127K 4,730 shares at $26.91 11% of stake
    Traded Jul 15 Filed Jul 17
    ↗
  10. Sue-Jean Lin Director
    Planned sale
    $121K 4,946 shares at $24.38 15% of stake
    Traded Jun 15 Filed Jun 17
    ↗
  11. Howard G. Welgus Director
    Planned sale
    $116K 4,731 shares at $24.58 11% of stake
    Traded Jun 15–17 Filed Jun 17
    ↗
  12. Masaru Matsuda See Remarks
    Planned sale
    $172K 7,372 shares at $23.27 5.5% of stake
    Traded May 4 Filed May 6
    ↗
  13. Howard G. Welgus Director
    Planned sale
    $164K 7,144 shares at $22.99 18% of stake
    Traded May 1 Filed May 5
    ↗
  14. Howard G. Welgus Director
    Planned sale
    $239K 10,000 shares at $23.88 20% of stake
    Traded Apr 1 Filed Apr 3
    ↗
  15. Keith R Leonard Director
    Planned sale
    $997K 39,272 shares at $25.39 64% of stake
    Traded Mar 2 Filed Mar 4
    ↗

Also filed in the last 12 months, not counted as buying or selling: 36 sales to cover taxes, 29 option exercises, 15 stock grants, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 9 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.07,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 4 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.